Skip to main content
Top
Published in: BMC Medicine 1/2016

Open Access 01-12-2016 | Opinion

Beyond viral suppression of HIV – the new quality of life frontier

Authors: Jeffrey V. Lazarus, Kelly Safreed-Harmon, Simon E. Barton, Dominique Costagliola, Nikos Dedes, Julia del Amo Valero, Jose M. Gatell, Ricardo Baptista-Leite, Luís Mendão, Kholoud Porter, Stefano Vella, Jürgen Kurt Rockstroh

Published in: BMC Medicine | Issue 1/2016

Login to get access

Abstract

Background

In 2016, the World Health Organization (WHO) adopted a new Global Health Sector Strategy on HIV for 2016–2021. It establishes 15 ambitious targets, including the ‘90-90-90’ target calling on health systems to reduce under-diagnosis of HIV, treat a greater number of those diagnosed, and ensure that those being treated achieve viral suppression.

Discussion

The WHO strategy calls for person-centered chronic care for people living with HIV (PLHIV), implicitly acknowledging that viral suppression is not the ultimate goal of treatment. However, it stops short of providing an explicit target for health-related quality of life. It thus fails to take into account the needs of PLHIV who have achieved viral suppression but still must contend with other intense challenges such as serious non-communicable diseases, depression, anxiety, financial stress, and experiences of or apprehension about HIV-related discrimination. We propose adding a ‘fourth 90’ to the testing and treatment target: ensure that 90 % of people with viral load suppression have good health-related quality of life. The new target would expand the continuum-of-services paradigm beyond the existing endpoint of viral suppression. Good health-related quality of life for PLHIV entails attention to two domains: comorbidities and self-perceived quality of life.

Conclusions

Health systems everywhere need to become more integrated and more people-centered to successfully meet the needs of virally suppressed PLHIV. By doing so, these systems can better meet the needs of all of their constituents – regardless of HIV status – in an era when many populations worldwide are living much longer with multiple comorbidities.
Literature
4.
go back to reference Kooij KW, Wit FWNM, Van Zoest RA, Schouten J, Kootstra N, Van Vugt M, et al. Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. AIDS. 2016. Epub ahead of print. Kooij KW, Wit FWNM, Van Zoest RA, Schouten J, Kootstra N, Van Vugt M, et al. Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine. AIDS. 2016. Epub ahead of print.
5.
go back to reference Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, AGEhIV Cohort Study Group, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59:1787–97.CrossRefPubMed Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, AGEhIV Cohort Study Group, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59:1787–97.CrossRefPubMed
6.
go back to reference Schouten J, Su T, Wit FW, Kootstra NA, Caan MWA, Geurtsen GJ, AGEhIV Study Group, et al. Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. AIDS. 2016;30:1027–38.CrossRefPubMed Schouten J, Su T, Wit FW, Kootstra NA, Caan MWA, Geurtsen GJ, AGEhIV Study Group, et al. Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. AIDS. 2016;30:1027–38.CrossRefPubMed
7.
go back to reference Erdbeer G, Sabranski M, Sonntag I, Stoehr A, Horst HA, Plettenberg A, et al. Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy. J Int AIDS Soc. 2014;17(4 Suppl 3):19673.PubMedPubMedCentral Erdbeer G, Sabranski M, Sonntag I, Stoehr A, Horst HA, Plettenberg A, et al. Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy. J Int AIDS Soc. 2014;17(4 Suppl 3):19673.PubMedPubMedCentral
8.
go back to reference Miners A, Phillips A, Kreif N, Rodger A, Speakman A, Fisher M, ASTRA (Antiretrovirals, Sexual Transmission and Attitudes) Study, et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV. 2014;1:e32–40.CrossRefPubMed Miners A, Phillips A, Kreif N, Rodger A, Speakman A, Fisher M, ASTRA (Antiretrovirals, Sexual Transmission and Attitudes) Study, et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV. 2014;1:e32–40.CrossRefPubMed
10.
go back to reference Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, Antiretroviral Therapy Cohort Collaboration,et al. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis. 2014;59:287–97.CrossRefPubMedPubMedCentral Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, Antiretroviral Therapy Cohort Collaboration,et al. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis. 2014;59:287–97.CrossRefPubMedPubMedCentral
11.
go back to reference van Lelyveld SFL, Gras L, Kesselring A, Zhang S, De Wolf F, Wensing AMJ, ATHENA national observational cohort study, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS. 2012;26:465–74.CrossRefPubMed van Lelyveld SFL, Gras L, Kesselring A, Zhang S, De Wolf F, Wensing AMJ, ATHENA national observational cohort study, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS. 2012;26:465–74.CrossRefPubMed
12.
go back to reference Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21:2483–91.CrossRefPubMed Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21:2483–91.CrossRefPubMed
13.
go back to reference Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? Analysis of 12 national level HIV treatment cascades. 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention. 19–22 July 2015. Vancouver, BC, Canada. Oral abstract MOAD0102. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? Analysis of 12 national level HIV treatment cascades. 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention. 19–22 July 2015. Vancouver, BC, Canada. Oral abstract MOAD0102.
15.
go back to reference Alleyne G, Binagwaho A, Haines A, Jahan S, Nugent R, Rojhani A, et al. Embedding non-communicable diseases in the post-2015 development agenda. Lancet. 2013;381:566–74.CrossRefPubMed Alleyne G, Binagwaho A, Haines A, Jahan S, Nugent R, Rojhani A, et al. Embedding non-communicable diseases in the post-2015 development agenda. Lancet. 2013;381:566–74.CrossRefPubMed
Metadata
Title
Beyond viral suppression of HIV – the new quality of life frontier
Authors
Jeffrey V. Lazarus
Kelly Safreed-Harmon
Simon E. Barton
Dominique Costagliola
Nikos Dedes
Julia del Amo Valero
Jose M. Gatell
Ricardo Baptista-Leite
Luís Mendão
Kholoud Porter
Stefano Vella
Jürgen Kurt Rockstroh
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2016
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-016-0640-4

Other articles of this Issue 1/2016

BMC Medicine 1/2016 Go to the issue